Piper Sandler Highlights Century Therapeutics (IPSC) Cash Runway Through 2029, Upcoming IND Submission

Century Therapeutics Inc. (NASDAQ:IPSC) is one of the best fast growing penny stocks to buy according to analysts. On January 20, Piper Sandler increased its price target for Century Therapeutics to $4 from $2 with an Overweight rating, citing the company’s plan to submit an IND for CNTY-813 this year and deliver initial data by 2027. Additionally, the firm highlighted Century’s strong financial position, estimating a pro forma cash balance of approximately $267 million that is expected to fund operations ...